99% Savings - Buy Just @1 Rs X
Mirbeg S 25 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Mirbeg S 25 Tablet safe for pregnant women?
Mirbeg S 25 Tablet may have some side effects during pregnancy. Pregnant women should discontinue the use of Mirbeg S 25 Tablet, and talk to their doctor, if they notice any discomfort.
Is the use of Mirbeg S 25 Tablet safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Mirbeg S 25 Tablet. Immediately discontinue Mirbeg S 25 Tablet if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Mirbeg S 25 Tablet on the Kidneys?
Mirbeg S 25 Tablet rarely harms the kidneys.
What is the effect of Mirbeg S 25 Tablet on the Liver?
Mirbeg S 25 Tablet has very mild side effects on the liver.
What is the effect of Mirbeg S 25 Tablet on the Heart?
Mirbeg S 25 Tablet has very mild side effects on the heart.
Mirbeg S 25 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Mirbeg S 25 Tablet unless your doctor advises you to do so -
Is this Mirbeg S 25 Tablet habit forming or addictive?
No, you will not get addicted to Mirbeg S 25 Tablet.
Interaction between Food and Mirbeg S 25 Tablet
Taking Mirbeg S 25 Tablet with food does not harm your health.
Interaction between Alcohol and Mirbeg S 25 Tablet
Consumption of alcohol and Mirbeg S 25 Tablet together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 864
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Myrbetriq (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Betmiga® (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; VESIcare® (solifenacin succinate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1151